Viking Therapeutics stock drops 40% amid trials

fool.com

Viking Therapeutics, developing weight loss drugs, has seen its stock drop about 40% this year. The company is working on injectable and oral versions of a drug called VK2735. Viking's drug is in the same class as popular weight loss treatments like Ozempic and Wegovy. Previous trial results for VK2735 have shown significant weight loss in participants. Viking recently finished enrolling patients in a phase 2 trial for its oral VK2735. The company anticipates reporting the results from this trial in the second half of 2025.


With a significance score of 3.1, this news ranks in the top 11% of today's 30550 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Viking Therapeutics stock drops 40% amid trials | News Minimalist